EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin

Miguel A García-González iD, Alejandro D Miguel-Martínez iD, Abimael González-Hernández iD, Magdalena Zamora iD, Elva Adán-Castro iD, Xarubet Ruíz-Herrera iD, María A Carbajo-Mata iD, Jakob Triebel iD, Thomas Bertsch iD, José G Lopez-Lopez iD, Gonzalo Martínez de la Escalera iD, Juan Pablo Robles iD und 2 weitere

Drug Development Research · 2025

DOI: 10.1002/ddr.70177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Miguel A García-González und 13 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Qro, Mexico. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by the Secretaría de Educación, Ciencia, Tecnología e Innovación de la Ciudad de México (SECTEI/061/2023). Moreover, the corresponding….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vasoinhibin is a potent antiangiogenic protein that blocks the activation of endothelial nitric oxide synthase (eNOS) in response to vascular endothelial growth factor, bradykinin, and acetylcholine (ACh). In this regard, VIAN‐c4551, a new synthetic vasoinhibin analog, has therapeutic potential for targeting angiogenesis in oncology and ophthalmology. Given that cardiovascular actions are common complications of antiangiogenic drugs and eNOS inhibitors, this multidisciplinary study investigated the cardiovascular safety of VIAN‐c4551. Administered acutely, VIAN‐c4551 inhibited ACh‐induced eNOS phosphorylation/activation in cultured endothelial cells and in lung tissue treated in vivo, as well as the ACh‐induced relaxation of rat aortic segments. However, daily intravenous (i.v.) injections of VIAN‐c4551 (1 or 3 mg kg −1 ) for 5 days failed to significantly modify the vasodepressor responses to ACh and the baseline values of blood pressure in anesthetized rats (intact, vagotomized, or pithed). Furthermore, daily i.v. injections of 1 mg kg −1 VIAN‐c4551 (for 5 days) did not alter: (i) blood pressure or heart rate values in awake rats; (ii) cardiac autonomic and histological outcomes in anesthetized animals; or (iii) inflammatory (tumor necrosis factor‐α [TNF‐α] and interleukin‐6 [IL‐6]) and apoptotic (caspase‐3) markers. Although VIAN‐c4551 inhibited ACh‐induced eNOS activation in vitro and in vivo and vasorelaxation in ex vivo assays, in vivo experiments consistently showed no significant cardiovascular effects produced by this synthetic peptide. Thus, VIAN‐c4551 appears to be cardiovascularly safe for targeting angiogenesis‐related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsAnimalsMaleNitric Oxide Synthase Type IIIRatsHumansBlood PressureRats, Sprague-DawleyHeart RateHuman Umbilical Vein Endothelial CellsLungCells, CulturedPhosphorylationVasodilationAcetylcholine

Stichwörter der Autor:innen

angiogenesis inhibitorscardiovascular riskvasoinhibin analog

Substanzen

Angiogenesis InhibitorsNitric Oxide Synthase Type IIIAcetylcholine

Autor:innen und Institutionen

  • Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Qro, Mexico.
  • Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Pue, Mexico.
  • Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Unidad Sede Sur, Mexico City, Mexico.
  • Laboratory Medicine and Transfusion Medicine, Institute for Clinical Chemistry, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
  • Departamento de Farmacia, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Pue, Mexico.
  • VIAN Therapeutics, San Francisco, California, USA.

ORCID-Profile: Miguel A García-González, Alejandro D Miguel-Martínez, Abimael González-Hernández, Magdalena Zamora, Elva Adán-Castro, Xarubet Ruíz-Herrera, María A Carbajo-Mata, Jakob Triebel, Thomas Bertsch, José G Lopez-Lopez, Gonzalo Martínez de la Escalera, Juan Pablo Robles, Carmen Clapp, Carlos M Villalón

Förderung

  • This study was supported by the Secretaría de Educación, Ciencia, Tecnología e Innovación de la Ciudad de México (SECTEI/061/2023). Moreover, the corresponding…

Zitieren

APA

García-González, M. A., Miguel-Martínez, A. D., González-Hernández, A., Zamora, M., Adán-Castro, E., Ruíz-Herrera, X., Carbajo-Mata, M. A., Triebel, J., Bertsch, T., Lopez-Lopez, J. G., Martínez de la Escalera, G., Robles, J. P., Clapp, C., & Villalón, C. M. (2025). Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin. Drug Development Research. https://doi.org/10.1002/ddr.70177

Vancouver

García-González MA, Miguel-Martínez AD, González-Hernández A, Zamora M, Adán-Castro E, Ruíz-Herrera X, et al. Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin. Drug Development Research. 2025. doi:10.1002/ddr.70177

BibTeX
@article{GarcaGonzlez2025,
  author = {García-González, Miguel A and Miguel-Martínez, Alejandro D and González-Hernández, Abimael and Zamora, Magdalena and Adán-Castro, Elva and Ruíz-Herrera, Xarubet and Carbajo-Mata, María A and Triebel, Jakob and Bertsch, Thomas and Lopez-Lopez, José G and Martínez de la Escalera, Gonzalo and Robles, Juan Pablo and Clapp, Carmen and Villalón, Carlos M},
  title = {Cardiovascular Safety of VIAN‐c4551, an Antiangiogenic Peptide Derived From Vasoinhibin},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70177}
}
Kostenlos starten →